CCO Annual Update
Hepatitis Annual Update 2004
Immunopathogenesis of Acute Hepatitis B and Hepatitis C |
Module 1 of 11 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Page 1
- Host Immune Response in HBV and HCV Infection
- The Liver as the Site of Antiviral Immune Response: Key Points
- Innate and Adaptive Immune Responses to HBV
- Innate and Adaptive Immune Responses to HCV
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the effect of host genetic factors on the variability of disease Distinguish innate and adaptive responses to hepatitis B and C virus Describe the host immune response to viral infection
|
HBV Treatment Guidelines: Questions and Controversies |
Module 2 of 11 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Creating Guidelines
- What Are the Goals of Treatment?
- Who Should Be Treated?
- HBeAg-negative patients
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the purpose of treatment guidelines and how guidelines are developed Discuss indications for treatment of acute and chronic hepatitis Discuss treatment options for acute and chronic hepatitis
|
New Data on Hepatitis B Virus Treatment |
Module 3 of 11 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Currently Available Treatments
- Interferon alfa
- Pegylated Interferon
- Nucleoside Analogues
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss preclinical anti-HBV agents. Describe drugs with anti-hepatitis B virus (HBV) activity that are already approved for other indications, including peginterferons, tenofovir disoproxil fumarate, emtricitabine, and thymosin alpha-1. Review other anti-HBV drugs that are currently in clinical trials, including telbivudine, entecavir, and clevudine.
|
Natural History, Diagnostics, and Clinical Profiles of Persons With Chronic Hepatitis B |
Module 4 of 11 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Natural History of Chronic HBV Infection
- Natural History of Chronic HBV: What's New
- Benefits of Antiviral Therapy
- High Viral Load
- HBeAg-negative Cases on Rise
Learning Objectives
Upon completion of this activity, participants should be able to:
Recognize clinical patterns of hepatitis B, including inactive carriers, HBeAg+ (with low vs high HBV DNA replication), and anti-HBe Describe the natural history of hepatitis B Discuss diagnostic methods and laboratory testing for hepatitis B, including the role of HBV DNA testing and genotyping
|
World Epidemiology of Hepatitis C |
Module 5 of 11 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Global Burden and Patterns of Infection
- Risk Factors for Transmission
- Healthcare-Related Infections
- Additional Risk Factors
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the different geographic patterns of age-specific prevalence of hepatitis C virus infection. Define the groups of persons at increased risk for hepatitis C virus infection for whom routine testing should be offered in countries with sufficient resources. Review the important modes of transmission of hepatitis C virus for countries with low, moderate, and high endemicity.
|
Hepatitis C Treatment: Today and Tomorrow |
Module 6 of 11 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Current Therapy for Hepatitis C
- Early Virologic Response
- Limitations of EVR
- New Directions in HCV Therapy
Learning Objectives
Upon completion of this activity, participants should be able to:
Evaluate strategies to improve treatment adherence and outcomes Describe current options for the treatment and management of chronic HCV infection Discuss the latest data about new drugs in development for the treatment of HCV infection
|
Impact of Nonalcoholic Fatty Liver Disease on Hepatitis C |
Module 7 of 11 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Steatosis and Hepatitis C
- Steatosis as a Modifier of Treatment Response
- Clinical Management
- Diagnosis: Measuring Insulin Resistance
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the relationship between steatosis and hepatitis C virus (HCV) in terms of effect of obesity on the natural history of HCV liver disease, and the relationship between steatosis and treatment of hepatitis C, including weight-based dosing adjustments. Discuss the relationship between diabetes and hepatitis C. Define fatty liver syndromes.
|
Cirrhosis and Beyond |
Module 8 of 11 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Outcome and Natural History Following Liver Transplantation for Hepatitis C
- Natural History
- Hepatitis C Recurrence After Liver Transplantation
- Preemptive Treatment Prior to Liver Transplantation
Learning Objectives
Upon completion of this activity, participants should be able to:
Establish prophylactic screening in cirrhotic patients for hepatocellular carcinoma and gastroesophageal varices. Understand the pros and cons of antiviral therapy in cirrhotic patients, including those awaiting liver transplantation. Understand recurrent hepatitis C and the natural history of this disease in the posttransplant recipient.
|
Hepatocellular Carcinoma |
Module 9 of 11 |
|
Program Director: John P. Phair, MD
- Adrian M. Di Bisceglie, MD, FACP
|
|
|
Topics covered include:
- Epidemiology
- Risk Factors for HCC
- Clinical Features and Diagnosis of HCC
- Treatment Options for HCC
- Screening and Preventing HCC
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the epidemiology of hepatocellular carcinoma (HCC) in the Unites States and abroad List the various risk factors for HCC Outline the various treatment options available for HCC
|
HIV Coinfection |
Module 10 of 11 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Epidemiology of HCV/HIV Coinfection
- Diagnosis of HCV Infection in HIV-Seropositive Individuals
- HCV: Pathogenic Interactions
- Natural History of HCV and HIV
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the complications of therapy for HBV and HCV coinfection in patients with HIV (including flares). Review the approach to treatment of coinfected patients, including management of antiretroviral therapy. Describe the diagnostic modalities for patients coinfected with HBV or HCV.
|
Drug Induced Hepatotoxicity: 2004 |
Module 11 of 11 |
|
Program Director: John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Spectrum of Hepatotoxicity Induced by Drugs
- Diagnosis of Drug-Induced Hepatic Injury
- Factors That Affect Susceptibility to Drug-Induced Liver Disease
- Mechanisms of Hepatotoxicity
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the hepatotoxic potential and signature for several commonly used drugs. Discuss regulatory procedures involved in drug development and approval with regard to assessment of hepatotoxicity. Outline the major advances leading to the current state of knowledge regarding drug-induced hepatotoxicity.
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|